[Pharmacokinetics of intravenous rifampicin (RMP) and its clinical evaluation in purulent bacterial meningitis].
A combined kinetic and clinical study showed that rifampicin displays good tissue diffusibility, though it may have a tendency to accumulate. A liquor transfer sufficient for the bacteria most commonly responsible for meningeal inflammation was observed; 15/18 cases of purulent bacterial meningitis treated were clinically cured without sequelae, while 1 displayed considerable improvement. Two patients died from unforseen, uncontrollable complications that were not related to administration of the drug.
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D008581:Meningitis / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage / Q000134:cerebrospinal fluid / Q000378:metabolism* / Q000627:therapeutic use; D014018:Tissue Distribution
D012293:Rifampin
Farmacocinetica della rifampicina (RMP) per via venosa e sua valutazione clinica in corso di menmingite purulenta batterica.